|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.79 CHF | -3.00% |
|
-19.07% | +97.38% |
| 20/06 | Top Premarket Gainers | MT |
| 17/06 | Transcript : Molecular Partners AG Presents at TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit, Jun-17-2024 10:40 AM |
Molecular Partners AG reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was CHF 2.74 million compared to CHF 3.05 million a year ago. Net loss was CHF 11.33 million compared to CHF 14.78 million a year ago.
Basic loss per share from continuing operations was CHF 0.34 compared to CHF 0.45 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +97.38% | 260M | |
| +16.57% | 122B | |
| +21.60% | 116B | |
| +22.18% | 27.03B | |
| -21.32% | 20.36B | |
| -16.89% | 16.43B | |
| -17.97% | 15.91B | |
| -44.74% | 15.6B | |
| +61.97% | 14.94B | |
| +3.50% | 13.59B |
MOLECULAR PARTNERS AG 
